Pfizer

Olivier Brandicourt appointed chairman of Bayer HealthCare

Tuesday, October 1, 2013 11:00 AM

Olivier Brandicourt has been appointed chairman of the board of management of Bayer HealthCare and member of the Bayer executive council effective Nov. 1. Since March, professor Wolfgang Plischke has led Bayer HealthCare on an interim basis in addition to his existing duties as a Bayer board member.

More... »

Theorem Clinical Research names Joseph Sgherza head of infectious diseases

Tuesday, October 1, 2013 09:44 AM

Global CRO Theorem Clinical Research has named Joseph Sgherza vice president of biopharmaceutical development for its infectious disease franchise. Sgherza has 24 years in the pharmaceutical, biotech and CRO industries.

More... »

Gliknik, Pfizer enter autoimmune disease licensing agreement

Monday, September 30, 2013 02:44 PM

Gliknik, a privately-held biopharmaceutical company, has entered into an exclusive worldwide licensing agreement with Pfizer for GL-2045, Gliknik's recombinant stradomer, a drug candidate that is designed to replace and improve on pooled human intravenous immunoglobulin (IVIG). GL-2045 has shown promising results in preclinical tests and is being developed as a potential treatment for a wide variety of autoimmune diseases, including those in which IVIG is clinically used.

More... »

Global Health Investment Fund launched for late-stage vaccines

Friday, September 27, 2013 10:59 AM

A new investment fund structured by JPMorgan Chase and the Bill & Melinda Gates Foundation will, for the first time, allow individual and institutional investors the opportunity to finance late-stage global health technologies that have the potential to save millions of lives in low-income countries.

More... »

Michael J. Fox Foundation unites industry groups for research tool development

Friday, September 13, 2013 01:07 PM

The Michael J. Fox Foundation for Parkinson's research (MJFF) has launched the Parkinson's Disease Research Tools Consortium. MJFF and seven industry partners have organized to grow the Foundation's ongoing efforts to better understand existing tools—such as preclinical models, antibodies and cell lines—and their use in laboratory experiments, as well as to develop new tools to address unmet challenges.

More... »

Oxford BioMedica earns milestone payment from Pfizer

Thursday, August 29, 2013 10:01 AM

Oxford BioMedica, a gene-based biopharmaceutical company, has announced a $1 million milestone payment from Pfizer has been triggered by the entry of PF-06263507, a 5T4-targeted investigational antibody therapy, into human clinical trials.

More... »

Amgen to acquire Onyx Pharmaceuticals

Monday, August 26, 2013 12:07 PM

Amgen will acquire San Francisco, Calif.-based Onyx Pharmaceuticals, purchasing all of the outstanding shares of Onyx for $125 per share in cash, for a total purchase price of $10.4 billion, or $9.7 billion net of estimated Onyx cash. The boards of both companies have approved the transaction.

More... »

Decision Resources suggests breast cancer market to reach $15B by 2022

Friday, August 23, 2013 11:39 AM

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of premium-priced agents will fuel 5% annual growth in the breast cancer market, with sales reaching more than $15 billion in 2022 in the U.S., France, Germany, Italy, Spain, the U.K. and Japan.

More... »

Assay Depot launches Pfizer virtual research platform

Friday, August 16, 2013 01:20 PM

Assay Depot, a provider of outsourced scientific services, has launched Market Exchange for Innovative Services (MXIS), a virtual outsourcing platform for Pfizer scientists. MXIS brings together research services from thousands of global vendors (aka CROs) into one secure website, enabling Pfizer scientists to communicate with any research vendor.

More... »

Sanford-Burnham, Pfizer collaborate

Thursday, August 15, 2013 11:14 AM

Sanford-Burnham Medical Research Institute has signed a three-year collaboration agreement with Pfizer to identify therapeutic targets for preventing and treating complications of obesity and diabetes. The team will utilize novel screening tools including systems-biology approaches and technologies developed at Sanford-Burnham with the aim of discovering therapeutic strategies for reducing insulin resistance in obesity and diabetes.

More... »